Insider James Pursley Files Form 4 for Hinge Health

TL;DR

**Insider James Pursley just filed a Form 4 for Hinge Health, signaling a potential change in his stake.**

AI Summary

This Form 4 filing, dated March 24, 2026, indicates that James Pursley, a reporting insider, has filed a statement of changes in beneficial ownership of securities for Hinge Health, Inc. (CIK: 0001673743). While the filing itself doesn't detail specific transactions, it signals that an insider's ownership stake may have changed, which is important for investors as insider activity can sometimes precede significant company events. This matters to stockholders because insider buying can signal confidence, while selling might suggest a lack of it, potentially influencing stock price movements.

Why It Matters

This filing signals potential changes in an insider's ownership, which can be a leading indicator of future company performance or sentiment. Investors often track these filings for insights into how those closest to the company view its prospects.

Risk Assessment

Risk Level: low — This filing is purely administrative, reporting a change in beneficial ownership, and does not inherently carry significant risk without transaction details.

Analyst Insight

A smart investor would note this filing and then look for subsequent filings or news that detail the specific transactions (e.g., buys or sells) made by James Pursley to understand the implications for Hinge Health, Inc. stock.

Key Players & Entities

• Pursley James (person) — Reporting insider
• Hinge Health, Inc. (company) — Issuer of securities
• 0001783108 (dollar_amount) — CIK for James Pursley
• 0001673743 (dollar_amount) — CIK for Hinge Health, Inc.

FAQ

Key Financial Figures

• $40.66 — est price at which shares were sold was $40.66 and the highest price at which shares w
• $41.62 — est price at which shares were sold was $41.62. The Reporting Person undertakes to pro
• $41.66 — est price at which shares were sold was $41.66 and the highest price at which shares w
• $42.65 — est price at which shares were sold was $42.65. The Reporting Person undertakes to pro
• $42.66 — est price at which shares were sold was $42.66 and the highest price at which shares w
• $42.86 — est price at which shares were sold was $42.86. The Reporting Person undertakes to pro

Filing Documents

• form4-03242026_110300.html (4)
• form4-03242026_110300.xml (4) — 8KB
• 0001783108-26-000010.txt ( ) — 9KB

From the Filing

SEC FORM 4 SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). X Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. 1. Name and Address of Reporting Person * Pursley James (Last) (First) (Middle) C/O HINGE HEALTH, INC. 455 MARKET STREET, SUITE 700 (Street) SAN FRANCISCO CALIFORNIA 94105 (City) (State) (Zip) UNITED STATES (Country) 2. Issuer Name and Ticker or Trading Symbol Hinge Health, Inc. [ HNGE ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) President 2a. Foreign Trading Symbol 3. Date of Earliest Transaction (Month/Day/Year) 03/23/2026 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person 4. If Amendment, Date of Original Filed (Month/Day/Year) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Class A Common Stock 03/23/2026 S (1) 2,256 D $ 41.2126 (2) 744,848 D Class A Common Stock 03/23/2026 S (1) 9,838 D $ 42.3571 (3) 735,010 D Class A Common Stock 03/23/2026 S (1) 2,906 D $ 42.7538 (4) 732,104 D Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Explanation of Responses: 1. The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 13, 2025. 2. Represents the weighted average sale price. The lowest price at which shares were sold was $40.66 and the highest price at which shares were sold was $41.62. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. 3. Represents the weighted average sale price. The lowest price at which shares were sold was $41.66 and the highest price at which shares were sold was $42.65. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. 4. Represents the weighted average sale price. The lowest price at which shares were sold was $42.66 and the highest price at which shares were sold was $42.86. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. /s/ James Budge, Attorney-in-Fact 03/24/2026 ** Signature of Reporting Person Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and

View Full Filing

View this 4 filing on SEC EDGAR